Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-90
SponsorRuijin Hospital

About this trial

This study is a multicentre, randomized, double-blind, controlled trial that aims to investigate the efficacy of multi-domain life-style intervention including low inflammatory-index diet, exercise, and cognitive training in patients with mild cognitive impairment and mild Alzheimer's disease.

Eligibility criteria

Qualifiers

Aged 60-90 years

In accordance with the diagnostic criteria for "mild cognitive impairment due to Alzheimer's disease" or "mild Alzheimer's disease" from the National Institutes of Health National Institute on Aging-Alzheimer's Association (NIA-AA) (2011)

The Hamilton depression rating scale/17 edition (HAMD) total score≤10

Neurological examination: no obvious signs

Disqualifiers

Other causes of cognitive decline: cerebrovascular disease, central nervous system infection, Creutzfeldt-Jakob disease, Huntington's and Parkinson's disease, Creutzfeldt-Jakob disease, traumatic brain dementia, other physical and chemical factors (such as drugs, alcohol, CO), systemic disease (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial occupation (a subdural hematoma, brain tumor), the endocrine system disease (thyroid disease, parathyroid disease), and vitamins deficiency or any other causes of dementia

The history of nervous system diseases, including stroke, optic myelitis, Parkinson's disease, epilepsy, etc

Psychiatric patients, including schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium

There are unstable or serious heart, lung, liver, kidney, endocrine, and hematopoietic system diseases, or Poor prognosis because of malignant diseases such as tumors.

Trial design

Treatments tested in this trial

  • Diet intervention
  • Exercise
  • Cognitive training

Treatment groups

180 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Ruijin Hospital

Lead sponsor

Shanghai Sinopharm Nursing Care Center

Collaborator